Prostate Cancer, Anderson, Dihydrotestosterone discussed on The Peter Attia Drive


Is converted via an enzyme called five after reduc days into a very similar molecule called dihydrotestosterone abbreviated DAT. Dat is actually any slightly more potent steroid and in men who fifty times more potent. Yeah. So the in men who are susceptible to baldness DHT, drives that process D H T also probably plays a role in the enlargement of the prostate is correct. Most of the five for duck days enzymes in the prostate. So yes, reducing Anderson's in the prostate by reducing effectively. Reducing DHT production reduces the size of the prostate. So a lot of guys take medication to reduce DHT either to reduce prostate volume size of something called benign prostatic, hypertrophy or to re minimize hair loss, and it's usually the exact same drug given it slightly different doses. And sometimes even come up with different names for the same drug. So proc-. Car is financed. Rated five milligrams. And I think pro-peace says the one milligram nets. Right. Okay. Now, I remember many years ago, and I don't I'm sure this has been revised one hundred times, but maybe ten years ago, maybe less, but a paper came out that said look in guys who have suppressed DAT levels when they get prostate cancer. They're more high-grade is at my remembering that correctly. And there's been definitely case reports of that. It's hard to really study that over I gotta yeah. So what is the current thinking on five algebra dictation habituation, and that relationship to prostate cancer? Well, there's was a very large randomized trial to see if you could take that medication with the idea that if you reduced the relative amount of Andhra Jensen the prostate by preventing the production of his potent androgen DAT. Could you reduce the risk of prostate cancer in those men and the answer was if you took that medicine that reduced potent Anderson? Hugh could. So there was a oatmeal study. This was in men starting out who did not have cancer. That's right. So it was called the prostate cancer prevention trial, and it was over seven years at the trial is conducted in Thompson was the PI on the trials of big study. It did reduce the chance at a man would develop prostate cancer overall, you know, reasonable amount of time. But one of the problems was that there was increased detection of more aggressive cancers in the men who are taking the finance. Right. And so then the question was, well, what is that? From is it inducing, a more high grade cancer, you know, and whether or not that's true or not as or is it selecting for it because any cancer that comes out of a low DHT environment. Well, yes. So I personally think that what you were just saying as is true. So yes, and there's case reports that people with low testosterone, or for example, people with low PSA's because PSA is only made when there's testosterone around, for example. That those individuals have more aggressive cancers. Now, this is what I've been focusing on in my lab for like the last four or five years now. And so one of the cool things we did in this collaboration with this company genome DX in this great, scientists alight of an she Oni was to look at the biology of prostate cancer, how grass if they were and compare the gresh Innis of the prostate cancer with the Anderson output of the tumor another nuanced way to normalize things a bit. Yep. And so we had this ipod uscis that the tumors that had the most amped up Anderson, signaling the most Anders output because prostate cancers and ginger tumor that they would be the most aggressive, and I say that way 'cause you know, the answer stieg's act posit the tumors with the lowest Anderton output or the are the most aggressive tumors. So it's somewhat relates to PSA, but not entire. Fairly like there's not a is on a true, you know, linear correlation. So the high Anders output tumors. They can be aggressive, but they are not as aggressive as Alterra low once's by modal distribution. And this is a good way to segue. Talking about these molecular tests because this is a commercially available test from genome DX might tell a funny story about ally. Before we go down there. Sure, I've told this story before but now we get to put a name to it..

Coming up next